Belimumab
Benlysta (belimumab) is a prescription medication from GlaxoSmithKline LLC, administered as a subcutaneous injection to inhibit B lymphocyte activation, helping manage autoimmune conditions like lupus. It comes in 200 mg/mL strength in prefilled syringes. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[ "009:10" ] |
| contactPoint |
{ "fn": "Division of Drug Information", "@type": "vcard:Contact", "hasEmail": "mailto:druginfo@fda.hhs.gov" } |
| description | Benlysta (belimumab) is a prescription medication from GlaxoSmithKline LLC, administered as a subcutaneous injection to inhibit B lymphocyte activation, helping manage autoimmune conditions like lupus. It comes in 200 mg/mL strength in prefilled syringes. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[ { "@type": "dcat:Distribution", "title": "Belimumab", "mediaType": "text/html", "description": " Access the FDA dataset for Belimumab — ANDA 125370 submitted by Mylan Institutional LLC ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125370" } ] |
| identifier | ANDA125370 |
| issued | 2016-09-16 |
| keyword |
[ "drug-information", "drug-manufacturers", "health-care", "medications", "public-health" ] |
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[ "009:002" ] |
| publisher |
{ "name": "U.S. Food and Drug Administration", "@type": "org:Organization" } |
| theme |
[ "FDA" ] |
| title | Belimumab |
